WATSU therapy for individuals with Parkinson's disease to improve quality of sleep and quality of life: A randomized controlled study
and Purpose: Sleep disorders are one of the most frequent non-motor symptoms of Parkinson's disease (PD). This study aimed to verify whether adding WATSU to land-based therapy leads to additional beneficial therapeutic effects regarding quality of sleep and quality of life (QOL) in individuals...
Saved in:
Published in: | Complementary therapies in clinical practice Vol. 46; p. 101523 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Elsevier Ltd
01-02-2022
Elsevier Science Ltd |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | and Purpose: Sleep disorders are one of the most frequent non-motor symptoms of Parkinson's disease (PD). This study aimed to verify whether adding WATSU to land-based therapy leads to additional beneficial therapeutic effects regarding quality of sleep and quality of life (QOL) in individuals with PD.
A randomized control trial design was used. Participants completed nine-week interventions. The control group (CG) received land-based therapy, while the intervention group (IG) received the same land-based therapy and additionally WATSU. Sleep quality and QOL were measured at baseline and post-interventions by Pittsburgh Sleep Quality Index and Nottingham Health Profile, respectively.
Twenty-eight participants completed the study. In contrast to CG, the IG presented with significant improvements in both, quality of sleep and QOL (p < 0.001).
WATSU has the potential to be an attractive adjunct therapy for producing positive health impacts regarding sleep quality, which may translate to an overall improvement in QOL of individuals with PD.
•Sleep disorders are the most common disabling non-motor symptoms of Parkinson's disease (PD).•WATSU therapeutic approach in a heated pool had positive effect in sleep quality of individuals with PD.•WATSU therapy should be considered an adjunct treatment for patients with PD. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 1744-3881 1873-6947 |
DOI: | 10.1016/j.ctcp.2021.101523 |